Skip to main content

Table 3 Correlations between changes in central biomarkers a

From: Peripheral and central effects of γ-secretase inhibition by semagacestat in Alzheimer’s disease

  Ventricular volume CSF p-tau CSF Aβ42 ADAScog11 MMSE
FDG-PET SUVR −0.43; 0.007 −0.14; 0.79 0.37; 0.47 −0.11; 0.36 0.23; 08
Ventricular volume 1; 0 −0.14; 0.62 −0.12; 0.67 0.46; 0.001 −0.54; 0.001
CSF p-tau   1; 0 0.37; 0.49 −0.40; 0.02 0.33; 0.05
CSF Aβ42    1; 0 −0.12; 0.48 0.31; 0.08
ADAScog11     1; 0 −0.58; 0.001
  1. aAβ42, Amyloid-β peptide 42; ADAScog11, Alzheimer’s Disease Assessment Scale–Cognitive Subscale, 11-item version; CSF, Cerebrospinal fluid; FDG-PET, Fludeoxyglucose positron emission tomography; MMSE, Mini Mental State Examination; p-tau, Phosphorylated tau; SUVR, Standard uptake value ratio. Data are Spearman’s correlation coefficients and P-values (r; P).